Medicare expands coverage for unproven cancer screening tests
S. 339 — Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act · Filed by Mike Crapo (R-ID) · 68 cosponsors · Introduced Jan 30, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare to cover multi-cancer early detection screening tests (blood tests that screen for multiple cancer types at once) starting January 1, 2028, for beneficiaries under age 68 (rising by one year annually). The tests must be FDA-cleared or approved and deemed medically necessary by the Centers for Medicare & Medicaid Services. Payment is initially pegged to the existing stool DNA screening test rate, then transitions to standard Medicare rates after 2031, with coverage limited to once per 11-month period.
Why we flagged it
The bill's core function is to mandate Medicare reimbursement for a new class of screening tests. While framed as a public-health measure, it is primarily a coverage mandate that will benefit diagnostic companies and test manufacturers, with uncertain clinical and fiscal impact on the Medicare program.
What the text implies
- The bill does not require prior clinical evidence of multi-cancer test efficacy before Medicare coverage begins (Jan 1, 2028), only FDA clearance/approval — a lower evidentiary bar than typical Medicare coverage decisions.
- The phased age-eligibility schedule (68 in 2028, rising 1 year annually) creates administrative complexity and potential inequity; younger seniors in 2028 will be ineligible while older cohorts in later years become eligible, inverting typical age-based access patterns.
The full analysis lists 5 implications of this text.
Who stands to gain
in vitro diagnostic (IVD) manufacturers; genomic sequencing companies; clinical laboratory service providers